Growth Hormone
Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Additional Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*ft* _____*inches*

Please indicate the place of service for the requested drug:
❑ *Ambulatory Surgical* ❑ *Home* ❑ *Inpatient Hospital* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

Criteria Questions:

1. What drug is being prescribed? ❑ Genotropin ❑ Humatrope ❑ Norditropin ❑ Nutropin AQ
   ❑ Omnitrope ❑ Saizen ❑ Zomacton ❑ Other _____
2. Is the growth hormone therapy being prescribed by or in consultation with one of the following specialists?
   ❑ Pediatric endocrinologist ❑ Endocrinologist ❑ Geneticist ❑ Pediatric nephrologist ❑ Gastroenterologist
   ❑ Nutritional support specialist ❑ Other _____
3. What is the diagnosis?
   ❑ Pediatric GHD (includes panhypopituitarism)
   ❑ Adult GHD (includes panhypopituitarism)
   ❑ Turner syndrome (TS)
   ❑ HIV-associated wasting/cachexia
   ❑ Noonan syndrome (NS)
   ❑ Short bowel syndrome (SBS)
   ❑ Small for gestational age (SGA)
   ❑ Prader-Willi syndrome (PWS)
   ❑ Growth failure associated with cerebral palsy (CP)
   ❑ Idiopathic short stature (ISS)
   ❑ Growth failure associated with cystic fibrosis (CF)
   ❑ SHOX deficiency (SHOXD)
   ❑ Growth failure associated with chronic kidney disease (CKD)
   ❑ Growth failure associated with congenital adrenal hyperplasia (CAH)
   ❑ Growth failure associated with Russell-Silver syndrome (RSS)
   ❑ Other _____

4. What is the ICD-10 code? _____ *If diagnosis is SBS, skip to section A.*

5. Is this request for continuation of therapy? ❑ Yes ❑ No *If No, skip to diagnosis section*

6. Is the patient currently receiving growth hormone through samples or a manufacturer's patient assistance program? ❑ Yes ❑ No ❑ Unknown *If Yes or Unknown, skip to diagnosis section*

7. Please indicate/attach the following information provided by the prescriber:
   A) Total duration of treatment (approximate duration is acceptable):

_____

   B) Date of the last dose administered: _____

   C) Approving health plan/pharmacy benefit manager: _____

   D) Date of the prior authorization/approval: _____

   E) **Attach** authorization approval letter

Complete the following section based on patient's diagnosis, if applicable.

Section A: Short Bowel Syndrome

8. Will somatropin be used in conjunction with optimal management of SBS? ❑ Yes ❑ No

9. How many weeks of GH therapy has the patient received in their lifetime? _____ weeks

Section B: Pediatric Disorders *Please complete the following sub-section, if applicable.*

10. Indicate patient's **pretreatment** height and age ***(two measurements taken at least 6 months apart)***:

    a) Height: _____ cm Age: _____ years, _____ months Date: _____

    b) Height: _____ cm Age: _____ years, _____ months Date: _____

11. Has patient had any **pretreatment** pharmacologic provocative tests? ❑ Yes, ***How many?*** _____ ❑ No
    ACTION REQUIRED: If Yes, attach laboratory report or medical record of pre-treatment provocative test results.

    ❑ Agent: _____ Peak Level: _____ ng/mL Date: _____

    ❑ Agent: _____ Peak Level: _____ ng/mL Date: _____

12. What is the **pretreatment** 1-year height velocity? _____ cm/year

13. Does the patient have a **pretreatment** slow growth velocity? ❑ Yes ❑ No

14. Are epiphyses still open? ❑ Yes ❑ No ❑ X-ray not available

15. Indicate patient's **current**: Height: _____ cm Age: _____ years, _____ months

16. *If currently on therapy*, is the patient growing more than 2 cm/year? ❑ Yes ❑ No
    Indicate therapy start date:_____
    If No, indicate clinical reason for the lack of efficacy: _____

I. Pediatric GHD (includes panhypopituitarism)

17. Is the patient a neonate or was the patient diagnosed with GH deficiency as a neonate?
    ❑ Yes ❑ No *If No, skip to #19*

18. Are medical records available to support the diagnosis of neonatal GH deficiency such as hypoglycemia with random GH level, evidence of multiple pituitary hormone deficiencies, MRI results, or chart notes?
    ❑ Yes ❑ No ***ACTION REQUIRED: If Yes, attach medical records.***

19. Does patient have a pituitary or CNS disorder? ***Indicate below or mark "No pituitary or CNS disorder."***

❑ Known mutation in GH-releasing hormone receptor, GH gene, GH receptor, or pituitary transcription factors
❑ CNS tumor/neoplasm (eg, craniopharyngioma, glioma, pituitary adenoma)
❑ Optic nerve hypoplasia/septo-optic dysplasia
❑ Empty sella syndrome
❑ Ectopic posterior pituitary
❑ Pituitary aplasia/hypoplasia
❑ Pituitary stalk defect
❑ Anencephaly or prosencephaly
❑ Other mid-line defect
❑ Vascular malformation
❑ Surgery
❑ Aneurysmal subarachnoid hemorrhage
❑ No pituitary or CNS disorder
❑ Agenesis of corpus callosum
❑ Cyst (Rathke cleft cyst or arachnoid cleft cyst)
❑ Radiation
❑ Chemotherapy
❑ CNS infection
❑ CNS infarction (e.g., Sheehan's syndrome)
❑ Inflammatory lesion (eg, autoimmune hypophysitis)
❑ Infiltrative lesion (eg, sarcoidosis, histiocytosis)
❑ Head trauma/traumatic brain injury
❑ Other _____

20. Does the patient have a **pretreatment** IGF-1 level greater than 2 SD below the mean? ❑ Yes ❑ No
ACTION REQUIRED: If Yes, attach laboratory report or medical record of pretreatment IGF-1 level.

*Indicate patient's **pretreatment** IGF-1 level:* _____ *Range:* _____

II. Turner Syndrome (TS)

21. Was the diagnosis of Turner syndrome confirmed by karyotyping? ❑ Yes ❑ No
ACTION REQUIRED: If Yes, attach karyotype study result.

III. SHOX Deficiency

22. Has the diagnosis of SHOX deficiency been confirmed by molecular or genetic analyses? ❑ Yes ❑ No
ACTION REQUIRED: If Yes, attach molecular/genetic test results.

IV. Prader-Willi Syndrome (PWS)

23. Was the diagnosis of Prader-Willi syndrome confirmed by genetic testing demonstrating any of the following?
ACTION REQUIRED: If Yes, attach genetic test result.
❑ Deletion in 15q11.2-q13 region
❑ Imprinting defects/translocations involving chromosome 15
❑ Maternal, uniparental disomy in chromosome 15
❑ None of the above

24. *If currently on therapy,* have body composition and psychomotor function improved or stabilized in response to GH therapy? ❑ Yes ❑ No ❑ N/A, not currently on therapy

V. Small for Gestational Age (SGA)

25. What was the patient's gestational age at birth? _____ weeks _____ days

26. What was the patient's: Birth Weight? _____ grams AND Birth Length? _____ cm

27. Did the patient fail to manifest catch-up growth by age two as demonstrated by **pretreatment** height greater than 2 SD below the mean for age and gender? ❑ Yes ❑ No

VI. Idiopathic Short Stature (ISS)

28. What is the patient's **pretreatment** predicted adult height? _____ feet, _____ inches

Section C: Adult Growth Hormone Disorder

29. Has patient had any **pretreatment** pharmacologic provocative tests? ❑ Yes, ***How many?*** ___ ❑ No, *skip to #31*
ACTION REQUIRED: If Yes, attach laboratory report or medical record of pre-treatment provocative test results.

❑ Agent: _____ Peak Level: _____ ng/mL Date: _____
❑ Agent: _____ Peak Level: _____ ng/mL Date: _____

30. Does the patient have a low **pretreatment** IGF-1 level for age and gender? ❑ Yes ❑ No
ACTION REQUIRED: If Yes, attach laboratory report or medical record of pretreatment IGF-1 level.
*Indicate patient's **pretreatment** IGF-1 level: _____ Range: _____*

31. Does the patient have a structural abnormality of the hypothalamus or pituitary gland? ❑ Yes ❑ No, *skip to #33*

32. Does the patient have deficiencies of greater than or equal to 3 pituitary hormones?
If Yes, indicate below and no further questions or mark "No deficiencies of pituitary hormones."
❑ Growth hormone ❑ Adrenocorticotropic hormone (ACTH) ❑ Antidiuretic hormone (ADH)
❑ Follicle stimulating hormone (FSH) ❑ Luteinizing hormone (LH) ❑ Thyroid stimulating hormone (TSH)
❑ Other _____
❑ No deficiencies of pituitary hormones, *continue to #33*

33. Did the patient have childhood-onset GHD? ❑ Yes ❑ No

34. Does the patient have a congenital abnormality of the hypothalamus or pituitary gland? ❑ Yes ❑ No

Section D: HIV-Related Wasting/Cachexia

35. Is the patient on anti-retroviral therapy? ❑ Yes ❑ No

36. Indicate the following:
Pretreatment : Height: _____ cm Weight: _____ lbs / kg BMI: _____ kg/m^2
Current: Height: _____ cm Weight: _____ lbs / kg BMI: _____ kg/m^2

37. *If new to GH therapy*, has the patient tried and had a suboptimal response to alternative therapies (ie, dronabinol, megesterol, cyproheptadine, or testosterone if hypogonadal)?
If Yes, no further questions ❑ Yes ❑ No ❑ N/A – patient is currently on GH therapy

38. Did the patient have a contraindication or intolerance to alternative therapies? ❑ Yes ❑ No

****Please attach the most recent clinical notes or supporting documentation****

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**